View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
June 8, 2020

ASCO 2020: Personalised treatment strategies in melanoma could reduce toxicity burden from immunotherapy without compromising benefits

By Victoria Smith

During ASCO 2020, held 29 May – 2 June, presentations in the melanoma field highlighted the efforts to reduce or optimise the use of ICIs with the intention to lessen excessive toxicities in patients. Study results suggest sometimes “less is more”, however, determining for which patient populations less treatment will be better is another question that needs to be answered.

A Phase II dose-sparing study presented by Michael A Postow, MD demonstrated that half of the recommended four-dose treatment with Opdivo + Yervoy combination could be adequate in provoking an anti-cancer immune response. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena